Sign up to save your podcasts
Or
Share ACCEL Lite: Featured ACCEL Interview With Douglas L. Mann and Javed Butler
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
ACCEL Lite: Featured ACCEL Interview With Douglas L. Mann and Javed Butler
In this interview, Douglas J. Mann and Javed Butler discuss the EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) trial and whether the risk of heart failure (HF) modulates the effectiveness of empagliflozin on HF hospitalization or cardiovascular death in patients with type 2 diabetes without HF.
View all episodes
By American College of Cardiology
3.7
5353 ratings
In this interview, Douglas J. Mann and Javed Butler discuss the EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) trial and whether the risk of heart failure (HF) modulates the effectiveness of empagliflozin on HF hospitalization or cardiovascular death in patients with type 2 diabetes without HF.
More shows like ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research
View all
JAMA Editors' Summary
133 Listeners
NEJM This Week
315 Listeners
JACC This Week
165 Listeners
This Week in Cardiology
861 Listeners
JAMA Clinical Reviews
488 Listeners
Mayo Clinic Talks
277 Listeners
The Curbsiders Internal Medicine Podcast
3,310 Listeners
JAMA Medical News
91 Listeners
Eagle's Eye View: Your Weekly CV Update From ACC.org
136 Listeners
Core IM | Internal Medicine Podcast
1,110 Listeners
ACC CardiaCast
37 Listeners
Annals On Call Podcast
191 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
349 Listeners
Cardionerds: A Cardiology Podcast
425 Listeners
Mayo Clinic Cardiovascular CME
35 Listeners